Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Lymphoma 113Leukemia 80Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Lymphoma, Non-Hodgkin 59Multiple Myeloma 56Leukemia, Myeloid, Acute 56Lymphoma, Large B-Cell, Diffuse 55Hodgkin Disease 48Myelodysplastic Syndromes 43Burkitt Lymphoma 43Lymphoma, Follicular 41Leukemia, Lymphocytic, Chronic, B-Cell 41Lymphoma, Mantle-Cell 40Breast Neoplasms 35Lymphoma, Large-Cell, Immunoblastic 34Sarcoma 27Neoplasms, Plasma Cell 27Central Nervous System Neoplasms 25Lymphoma, B-Cell, Marginal Zone 24Dendritic Cell Sarcoma, Interdigitating 19Recurrence 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Ovarian Neoplasms 16Neuroblastoma 16Myeloproliferative Disorders 16Leukemia, Myeloid, Chronic-Phase 16Leukemia, Myeloid, Accelerated Phase 15Congenital Abnormalities 15Neutropenia 13Lung Neoplasms 13

Interventions

Imatinib Mesylate 3ruxolitinib 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Dasatinib 1Cytarabine 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hypereosinophilic Syndrome × Filgrastim × Clear all
NCT00483067 2012-08-02

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

M.D. Anderson Cancer Center

Phase 2 Completed
13 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡